Company: STAA
Filing Date: 2025-11-04
Form Type: DFAN14A
Source: 0001104659-25-105834
Chunk: 6

Company: STAAR SURGICAL CO
Filing Date: 2025-11-04
Form: DFAN14A
Chunk 6
---
 of the proposed transaction to be delayed or to fail to occur; (2) the failure to obtain approval of the proposed transaction from STAAR’s stockholders; (3) the failure to obtain certain required regulatory approvals or the failure to sati sfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all; (4) risks related to disruption of management’s attention from STAAR’s ongoing business op era tions due to the proposed transaction; (5) the effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel and maintain relationships with its customers, sup pliers and others with whom it does business, or on its operating results and business generally; (6) the ability of STAAR to meet expectations regarding the timing and completion of the transaction; (7) th e outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction; (8) the possibility that STAAR’s stock price may decline significantly if the proposed transaction is n ot consummated; and (9) other important factors set forth in the Proxy Statement under the caption “Risk Factors” and STAAR’s Annual Report on Form 10 - K for the year ended December 27, 2024 under the caption “Risk F actors,” as any such factors may be updated from time to time in STAAR’s other filings with the SEC. Forward - looking statements speak only as of the date they are made and, except as may be required under applicable law, neither Alcon nor STAAR undertakes any obligation to update or revise any forward - looking statements, whether as a result of new information, future events or otherwise.

3 Summary 1. Alcon estimates 2. STAAR Investor Presentation, March 2024; Growth estimate based on 2023 actual and $525m (midpoint of $500 - 550m guidance for 2026 ) 3. STAAR Management Presentation: Alcon Merger Maximizes Value for Stockholders of STAAR Surgical – September 2025 4. Federal Reserve Economic Data, Federal Reserve Bank of St. Louis; Mid - year update: Five surprises from China’s consumer market 5. Alcon estimates – based on STAAR revenue release October 20, 2025 ▪ Despite STAAR being in play since July 2024, Alcon remains the only interested buyer 3 ▪ Alcon has recommended a 45 - day go - shop period without matching